Full-Time

Sr Associate User Experience Design

Updated on 5/13/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Software Engineering (1)
Required Skills
Dynamodb
FastAPI
Python
JavaScript
React.js
NoSQL
Redux.js
Figma
SQL
Java
GraphQL
TypeScript
Microservices
AWS
JIRA
Vue.js
OpenAPI
REST APIs
AngularJS
Databricks
HTML/CSS
Requirements
  • Master’s degree in computer science & engineering preferred with 4-6 years of software development experience OR, Bachelor’s degree in computer science & engineering preferred with 5-7 years of software development experience
  • Minimum 3+years of experience as an UI-UX designer
  • Relevant experience or education in UX Design, Product Design
  • Hands on experience with Javascript,React, CSS HTML , Lucid Chart, Figma designing
  • Proficient in programming language React Framework Redux, Graphql, RESTful API Development, Swagger / OpenAPI , Java Microservices API, Java Crawlers, TypeScript, Fast Python , Java Script, SQL/NoSQL ,Dynamo DB, S3, Databricks, RDS ,GCP Cloud Search, Solr Search, GCP Cloud engine
  • Strong problem solving, analytical skills; Ability to learn quickly; Excellent communication and interpersonal skills
Responsibilities
  • Design elegant, user-friendly interfaces for search platforms that enable users to explore complex scientific and medical data.
  • Translate user research, business needs, and technical requirements into wireframes, mockups, and high-fidelity prototypes
  • Develop responsive and dynamic UI components using modern frontend frameworks (e.g., React, Angular, Vue).
  • Integrate with search backends, APIs, and visualization tools to display search results, filters, ontologies, and metadata.
  • Ensure UI performance, accessibility (WCAG/Section 508 compliance), and cross-browser compatibility.
  • Design intuitive query experiences including search bars, faceted navigation, filters, result ranking, and interactive content previews
  • Collaborate with AI/ML teams to integrate advanced features such as semantic search, auto-suggestions, Q&A interfaces, and generative answers
  • conduct usability testing, A/B testing, and collect user feedback to continuously improve UX.
  • Analyze usage data and search behavior to drive data-informed UX enhancements.
  • Design and deliver high-quality UI/UX solutions for web
  • Create wireframes, interactive prototypes, and user flows.
  • Conduct user research, usability testing, and competitive analysis to enhance user experience
  • Analyze and identify pain points from the users’ perspective by conducting user research through interviews, observations, Gemba walks and other research methods
  • Create Personas, Journey maps, empathy maps, and process maps of current and to-be state
  • Ensure pixel-perfect, responsive, innovative, and interactive designs across different devices and platforms.
  • Maintain design consistency and adhere to brand guidelines.
  • Create Sketches, Wireframes, Mockups and Prototypes, ranging from low fidelity to high-fidelity based on the needs.
  • Produce pixel-perfect interactive prototypes, Visual style guides, Icons and Red lines (Design specifications for developers)
  • Ensure accessibility, SEO-friendly design, and usability best practices.
  • Prepare and maintain necessary documents.
  • Understand the business objectives and rationales behind high level product features; translate them into user flows, wireframes, mock-ups, and prototypes that lead to intuitive and easy-to-use user experiences
  • Follow Amgen design standards and style guides to produce comprehensive deliverables encompassing user flows and UI wireframes to facilitate software development
  • Familiarity with data mapping, transformation, and ETL processes
  • Proficiency in SQL is highly valued: you don't need to be able to write SQL from scratch, but you should be able to interpret statements to assist in troubleshooting
  • Experience with data governance principles will be highly valued.
  • Understanding of database structures.
  • Experience in overseeing the design and configuration of tests to measure incremental performance as well as configuring metadata to enable their measurement.
  • How data can be used to power personalized experiences.
  • Tools you will be using will include Jira, Figma, Lucidchart,CSS HTML ,Javascript .
  • expertise in creating intuitive, user-friendly interfaces and seamless user experiences.
  • Convert complex requirements into elegant, intuitive, and functional designs. Provide ongoing support and maintenance for applications, ensuring that they operate smoothly and efficiently.
  • Informing various stakeholders about any problems with the current technical solutions being implemented.
  • Take ownership and accountability of the deliverables
Desired Qualifications
  • Experience in HTML, CSS, and JavaScript for developing basic static re-usable UI components
  • Experience in Angular & React.js for creating reusable components, Databricks, SQL
  • Experience with Web site development, understand of web site localization process
  • Experience with DevOps CICD build and deployment pipeline
  • Experience in Agile software development methodologies
  • Ability to communicate all phases of UX design, from initial concept through detailed screen designs. Excellent interaction design skills. Experience designing for technical or expert users.
  • Detail oriented & Critical thinker.
  • Problem solver, empathetic and is user centric
  • Willingness to work on AI Applications
  • Experience GXP Search Engine/ Solr Search
  • Experience in Posgres SQL /Mongo DB SQL database, vector database for large language models, Databricks or RDS , Dynamo DB , S3
  • Experience with Langchain or llamaIndex framework for language models
  • Experience with prompt engineering, model fine tuning
  • Knowledge of NLP techniques for text analysis and sentiment analysis
  • Willingness to work on AI Applications
  • Experience GXP Search Engine/ Solr Search

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.